Instituto Privado Kremer

Running trials

• Recruiting

  A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

  NCT07091630· Phase 3· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

  NCT06920004· Phase 3· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  NCT07011732· Phase 3· Source

• Recruiting

  A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  NCT06585787· Phase 3· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Source

• Active, not recruiting

  A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06132893· Phase 2/3· Source

• Recruiting

  A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

  NCT04462770· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease2 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)2 recruiting
• Epilepsy2 recruiting
• Schizophrenia1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

  NCT05744401· Phase 2· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Source